1Jain RK.Molecular recognition of vessel maturation.Nat Med,2003,9:685-693.
2Ferrara N.VEGF:an update on biological and therapeutic aspects.Curr Opin Biotechnol,2000,11:617 -624.
3Gordon MS,Margolin K,Talpaz M,et al.Phase Ⅰ safety and pharmacokinetic study of recombinant human anti-Vascular Endothelial Growth Factor in patient with advanced cancer.Joumal of Clincal Oncology,2001,3(19):843.
4Johnson DH,Fehrenbacher L,Novotny W,et al Randomized Phase Ⅱtrial comparing Bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell-lung-cancer.J Clin Oncol,2004,22 (11):2184.
5Herbst RS,Johnson DH,Mininberg E,et al.Phase Ⅰ/Ⅱ trial evaluating the anti-vascular endothelial growth factor monoclonal antibody Bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor growth factor receptor tyrosine kinase inhibitor Erlotinib for patients with recurrent non-small-cell-lung cancer.J Clin Oncol,2005,23(11):2544-2555.
6Alan Sandler,Robert Gray,Michael C.Perry,et al.Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer.N Engl J Med,2007,356(3):318.
7D'Adamo DR,Anderson SE,Albritton K,et al.Phase Ⅱ study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.J Clin Oncol,2005,23 (28):7135.
